PDF(Pubmed)
Abstract：
OBJECTIVE: This study aims to investigate the clinical and pathological characteristics, treatment approaches, and prognosis of gallbladder neuroendocrine carcinoma (GB-NEC).
METHODS: Retrospective analysis was conducted on the clinical data of 37 patients with GB-NEC admitted to Shanxi Cancer Hospital from January 2010 to June 2023. The study included an examination of their general information, treatment regimens, and overall prognosis.
RESULTS: Twelve cases, either due to distant metastasis or other reasons, did not undergo surgical treatment and received palliative chemotherapy (Group 1). Two cases underwent simple cholecystectomy (Group 2); four patients underwent palliative tumor resection surgery (Group 3), and nineteen patients underwent radical resection surgery (Group 4). Among the 37 GB-NEC patients, the average pre-surgery CA19-9 level was 113.29 ± 138.45 U/mL, and the median overall survival time was 19 months (range 7.89-30.11 months). Of these, 28 cases (75.7%) received systemic treatment, 25 cases (67.6%) underwent surgical intervention, and 16 cases (64.0%) received postoperative adjuvant treatment, including combined radiochemotherapy or chemotherapy alone. The median overall survival time was 4 months (0.61-7.40 months) for Group 1 (n = 12), 8 months for Group 2 (n = 2), 21 months (14.67-43.33 months) for Group 3 (n = 4), and 19 months (range 7.89-30.11 months) for Group 4 (n = 19). A significant difference in median overall survival time was observed between Group 1 and Group 4 (P = 0.004).
CONCLUSIONS: Surgery remains the primary treatment for GB-NEC, with radical resection potentially offering greater benefits to patient survival compared to other therapeutic options. Postoperative adjuvant therapy has the potential to extend patient survival, although the overall prognosis remains challenging.
METHODS: Retrospective analysis was conducted on the clinical data of 37 patients with GB-NEC admitted to Shanxi Cancer Hospital from January 2010 to June 2023. The study included an examination of their general information, treatment regimens, and overall prognosis.
RESULTS: Twelve cases, either due to distant metastasis or other reasons, did not undergo surgical treatment and received palliative chemotherapy (Group 1). Two cases underwent simple cholecystectomy (Group 2); four patients underwent palliative tumor resection surgery (Group 3), and nineteen patients underwent radical resection surgery (Group 4). Among the 37 GB-NEC patients, the average pre-surgery CA19-9 level was 113.29 ± 138.45 U/mL, and the median overall survival time was 19 months (range 7.89-30.11 months). Of these, 28 cases (75.7%) received systemic treatment, 25 cases (67.6%) underwent surgical intervention, and 16 cases (64.0%) received postoperative adjuvant treatment, including combined radiochemotherapy or chemotherapy alone. The median overall survival time was 4 months (0.61-7.40 months) for Group 1 (n = 12), 8 months for Group 2 (n = 2), 21 months (14.67-43.33 months) for Group 3 (n = 4), and 19 months (range 7.89-30.11 months) for Group 4 (n = 19). A significant difference in median overall survival time was observed between Group 1 and Group 4 (P = 0.004).
CONCLUSIONS: Surgery remains the primary treatment for GB-NEC, with radical resection potentially offering greater benefits to patient survival compared to other therapeutic options. Postoperative adjuvant therapy has the potential to extend patient survival, although the overall prognosis remains challenging.
摘要：
目的：本研究旨在探讨临床和病理特征，治疗方法,胆囊神经内分泌癌（GB-NEC）的预后。
方法：回顾性分析2010年1月至2023年6月山西省肿瘤医院收治的37例GB-NEC患者的临床资料。这项研究包括检查他们的一般信息，治疗方案,和总体预后。
结果：12例，由于远处转移或其他原因，未接受手术治疗并接受姑息性化疗(第1组).2例患者行单纯胆囊切除术（第2组）；4例患者行姑息性肿瘤切除术（第3组），19例患者接受了根治性切除手术（第4组）。在37名GB-NEC患者中，术前平均CA19-9水平为113.29±138.45U/mL,中位总生存时间为19个月(范围7.89-30.11个月)。其中,28例（75.7%）接受全身治疗，25例(67.6%)接受手术干预,16例(64.0%)接受术后辅助治疗,包括联合放化疗或单独化疗。第1组（n=12）的中位总生存时间为4个月（0.61-7.40个月），第2组（n=2）为8个月，第3组（n=4）为21个月（14.67-43.33个月），第4组（n=19）为19个月（范围7.89-30.11个月）。在第1组和第4组之间观察到中位总生存时间的显著差异(P=0.004)。
结论：手术仍然是GB-NEC的主要治疗方法，与其他治疗选择相比，根治性切除术可能为患者生存提供更大的益处。术后辅助治疗有可能延长患者的生存期，尽管总体预后仍然具有挑战性.
方法：回顾性分析2010年1月至2023年6月山西省肿瘤医院收治的37例GB-NEC患者的临床资料。这项研究包括检查他们的一般信息，治疗方案,和总体预后。
结果：12例，由于远处转移或其他原因，未接受手术治疗并接受姑息性化疗(第1组).2例患者行单纯胆囊切除术（第2组）；4例患者行姑息性肿瘤切除术（第3组），19例患者接受了根治性切除手术（第4组）。在37名GB-NEC患者中，术前平均CA19-9水平为113.29±138.45U/mL,中位总生存时间为19个月(范围7.89-30.11个月)。其中,28例（75.7%）接受全身治疗，25例(67.6%)接受手术干预,16例(64.0%)接受术后辅助治疗,包括联合放化疗或单独化疗。第1组（n=12）的中位总生存时间为4个月（0.61-7.40个月），第2组（n=2）为8个月，第3组（n=4）为21个月（14.67-43.33个月），第4组（n=19）为19个月（范围7.89-30.11个月）。在第1组和第4组之间观察到中位总生存时间的显著差异(P=0.004)。
结论：手术仍然是GB-NEC的主要治疗方法，与其他治疗选择相比，根治性切除术可能为患者生存提供更大的益处。术后辅助治疗有可能延长患者的生存期，尽管总体预后仍然具有挑战性.
